Cerus Corporation
Cerus Corporation sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 2 trials.
Trial Pipeline
10 total, page 1 of 1
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
NCT07015437
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
NCT03037164
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
NCT07218185
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
NCT06697223
In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
NCT04022889
Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
NCT03459287
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
NCT02549222
A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study
NCT02653443
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
NCT02295501
A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells
NCT01711346
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 2 |
Therapeutic Areas
What the Pipeline for Cerus Corporation Shows
According to the ClinicalTrials.gov registry, Cerus Corporation is linked to 10 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting, about 10% of the sponsor's indexed portfolio, and 5 are already marked complete, representing roughly 50% of the total.
The phase mix for Cerus Corporation reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 6 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Cerus Corporation is Healthy Subjects with 2 linked trials, and 1 other condition area appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.